Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis.
Phase of Trial: Phase III
Latest Information Update: 13 May 2016
At a glance
- Drugs Alogliptin (Primary) ; Antihyperglycaemics
- Indications Atherosclerosis; Cardiovascular disorders; Diabetic angiopathies; Type 2 diabetes mellitus
- Focus Biomarker; Therapeutic Use
- Acronyms SPEAD-A
- 25 Mar 2016 Status changed from active, no longer recruiting to completed.
- 01 Dec 2015 Results published in the Diabetes Care
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.